Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tatsuya Maruhashi is active.

Publication


Featured researches published by Tatsuya Maruhashi.


Circulation-cardiovascular Interventions | 2011

Autologous Bone-Marrow Mononuclear Cell Implantation Reduces Long-Term Major Amputation Risk in Patients With Critical Limb Ischemia A Comparison of Atherosclerotic Peripheral Arterial Disease and Buerger Disease

Naomi Idei; Junko Soga; Takaki Hata; Yuichi Fujii; Noritaka Fujimura; Shinsuke Mikami; Tatsuya Maruhashi; Kenji Nishioka; Takayuki Hidaka; Yasuki Kihara; Moniruddin Chowdhury; Kensuke Noma; Akira Taguchi; Kazuaki Chayama; Taijiro Sueda; Yukihito Higashi

Background— Bone-marrow mononuclear cell (BM-MNC) implantation improves ischemic symptoms in patients with critical limb ischemia (CLI). The purpose of this study was to evaluate long-term clinical outcomes after autologous BM-MNC implantation in patients with CLI. Methods and Results— We assessed long-term clinical outcomes after BM-MNC implantation in 51 patients with CLI, including 25 patients with peripheral arterial disease (PAD) and 26 patients with Buerger disease. Forty-six CLI patients who had no BM-MNC implantation served as control subjects. Median follow-up period was 4.8 years. The 4-year amputation-free rates after BM-MNC implantation were 48% in PAD patients and 95% in Buerger disease, and they were 0% in control PAD patients and 6% in control Buerger disease. The 4-year overall survival rates after BM-MNC implantation were 76% in PAD patients and 100% in Buerger disease, and they were 67% in control PAD patients and 100% in control Buerger disease. Multivariable Cox proportional hazards analysis revealed that BM-MNC implantation correlated with prevention of major amputation and that hemodialysis and diabetes mellitus correlated with major amputation. In Buerger disease, ankle brachial pressure index and transcutaneous oxygen pressure were significantly increased after 1 month and remained high during 3-year follow-up. However, in patients with PAD, ankle brachial pressure index and transcutaneous oxygen pressure significantly increased after 1 month and gradually decreased during 3-year follow-up and returned to baseline levels. Conclusions— These findings suggest that BM-MNC implantation is safe and effective in patients with CLI, especially in patients with Buerger disease. Clinical Trial Registration— URL: . Unique identifier: 001769.Background—Bone-marrow mononuclear cell (BM-MNC) implantation improves ischemic symptoms in patients with critical limb ischemia (CLI). The purpose of this study was to evaluate long-term clinical outcomes after autologous BM-MNC implantation in patients with CLI. Methods and Results—We assessed long-term clinical outcomes after BM-MNC implantation in 51 patients with CLI, including 25 patients with peripheral arterial disease (PAD) and 26 patients with Buerger disease. Forty-six CLI patients who had no BM-MNC implantation served as control subjects. Median follow-up period was 4.8 years. The 4-year amputation-free rates after BM-MNC implantation were 48% in PAD patients and 95% in Buerger disease, and they were 0% in control PAD patients and 6% in control Buerger disease. The 4-year overall survival rates after BM-MNC implantation were 76% in PAD patients and 100% in Buerger disease, and they were 67% in control PAD patients and 100% in control Buerger disease. Multivariable Cox proportional hazards analysis revealed that BM-MNC implantation correlated with prevention of major amputation and that hemodialysis and diabetes mellitus correlated with major amputation. In Buerger disease, ankle brachial pressure index and transcutaneous oxygen pressure were significantly increased after 1 month and remained high during 3-year follow-up. However, in patients with PAD, ankle brachial pressure index and transcutaneous oxygen pressure significantly increased after 1 month and gradually decreased during 3-year follow-up and returned to baseline levels. Conclusions—These findings suggest that BM-MNC implantation is safe and effective in patients with CLI, especially in patients with Buerger disease. Clinical Trial Registration—URL: http://home.hiroshima-u.ac.jp/angio/. Unique identifier: 001769.


Circulation | 2012

Hyperbilirubinemia, Augmentation of Endothelial Function, and Decrease in Oxidative Stress in Gilbert Syndrome

Tatsuya Maruhashi; Junko Soga; Noritaka Fujimura; Naomi Idei; Shinsuke Mikami; Yumiko Iwamoto; Masato Kajikawa; Takeshi Matsumoto; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; Ayumu Nakashima; Hirofumi Tomiyama; Bonpei Takase; Akira Yamashina; Yukihito Higashi

Background— Patients with Gilbert syndrome have mild unconjugated hyperbilirubinemia. It has been shown that bilirubin is an endogenous antioxidant. We evaluated the role of oxidative stress in endothelial function in patients with Gilbert syndrome under normal conditions without cardiovascular risk factors. Methods and Results— A total of 108 young men with Gilbert syndrome without cardiovascular risk factors and 108 age-matched healthy men (normal controls) were enrolled in this study. Serum concentrations of bilirubin were higher in patients with Gilbert syndrome than in control subjects (29.2±11.6 versus 9.4±2.7 &mgr;mol/L; P<0.001). Serum concentrations of malondialdehyde-modified low-density lipoprotein and urinary excretion of 8-hydroxy-2′-deoxyguanosine (8-OHdG), as indices of oxidative stress, were lower in patients with Gilbert syndrome than in control subjects (61.8±24.5 versus 72.5±21.8 U/L, P=0.034; 7.8±2.4 versus 10.4±3.2 ng/mg creatinine, P=0.001, respectively). Flow-mediated vasodilation was greater in patients with Gilbert syndrome than in normal control subjects (7.2±2.2% versus 5.9±1.7%; P<0.001). Vascular responses to nitroglycerine were not significantly different between the 2 groups. Flow-mediated vasodilation correlated with serum concentration of bilirubin (r=0.44, P<0.001), malondialdehyde-modified low-density lipoprotein (r=−0.25, P=0.01), and urinary excretion of 8-OHdG (r=−0.27, P=0.004) in patients with Gilbert syndrome but not in control subjects. In addition, serum concentration of bilirubin correlated with malondialdehyde-modified low-density lipoprotein (r=−0.20, P=0.04) and 8-OHdG (r=−0.21, P=0.02) in patients with Gilbert syndrome but not in control subjects. Conclusions— Patients with Gilbert syndrome had low levels of oxidative stress associated with hyperbilirubinemia and enhancement of endothelium-dependent vasodilation. Clinical Trial Registration— URL: http://www.umin.ac.jp. Unique identifier: UMIN000003409.


Coronary Artery Disease | 2009

Prevalence of incidental coronary artery disease in tako-tsubo cardiomyopathy.

Satoshi Kurisu; Ichiro Inoue; Takuji Kawagoe; Masaharu Ishihara; Yuji Shimatani; Yasuharu Nakama; Tatsuya Maruhashi; Eisuke Kagawa; Kazuoki Dai; Junichi Matsushita; Hiroki Ikenaga

ObjectiveEarlier studies have often required the absence of obstructive coronary artery disease (CAD) as the criteria. However, it is probable that patients with tako-tsubo cardiomyopathy have an incidental CAD because most patients are elderly. We assessed the prevalence of incidental CAD. MethodsWe reviewed coronary angiograms of 97 Japanese patients with tako-tsubo cardiomyopathy. A wrapped left anterior descending artery (LAD) was defined as a LAD that perfused at least one-quarter of the inferior wall of the left ventricle in the 30° right anterior oblique projection. ResultsTen patients (10%) had definitively incidental CAD defined as greater than 75% reduction in the luminal diameter of the major epicardial coronary artery. All patients had ST-segment elevation, and five patients had T-wave inversion on admission. Nine patients had single vessel disease, and one patient had double vessel disease. Six patients had CAD in the nonwrapped LAD, and they were judged to be definitively incidental. Three patients had CAD in the left circumflex artery, and two patients had CAD in the right coronary artery. ConclusionThis study showed that incidental CAD was found in 10% of Japanese patients with tako-tsubo cardiomyopathy. In patients with CAD in the LAD, it should be carefully judged whether the CAD causes left ventricular apical ballooning to avoid performing coronary revascularization unnecessarily.


International Journal of Cardiology | 2011

Incidence and treatment of left ventricular apical thrombosis in Tako-tsubo cardiomyopathy

Satoshi Kurisu; Ichiro Inoue; Takuji Kawagoe; Masaharu Ishihara; Yuji Shimatani; Yasuharu Nakama; Tatsuya Maruhashi; Eisuke Kagawa; Kazuoki Dai

Among 95 patients with Tako-tsubo cardiomyopathy, left ventricular (LV) apical thrombus was documented in 5 (5.3%) patients. The thrombus was mural in 2 (40%), and protruding in 3 (60%) patients. In 4 patients, LV apical thrombus disappeared after anticoagulant therapy. In one patient with protruding thrombus, brain infarction occurred. LV dysfunction was resolved during follow-up in all patients.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2013

Nitroglycerine-Induced Vasodilation for Assessment of Vascular Function A Comparison With Flow-Mediated Vasodilation

Tatsuya Maruhashi; Junko Soga; Noritaka Fujimura; Naomi Idei; Shinsuke Mikami; Yumiko Iwamoto; Masato Kajikawa; Takeshi Matsumoto; Takayuki Hidaka; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; Ayumu Nakashima; Chikara Goto; Yukihito Higashi

Objective—Nitroglycerine-induced vasodilation has been used as a control test for flow-mediated vasodilation (FMD) to differentiate endothelium-dependent from endothelium-independent response when evaluating endothelial function in humans. Recently, nitroglycerine-induced vasodilation has also been reported to be impaired in patients with atherosclerosis. The purpose of this study was to determine the relationships between nitroglycerine-induced vasodilation and cardiovascular risk factors. Approach and Results—We measured nitroglycerine-induced vasodilation and FMD in 436 subjects who underwent health examinations (mean age, 53±19 years; age range, 19–86 years), including patients with cardiovascular diseases. There was a significant relationship between nitroglycerine-induced vasodilation and FMD (r=0.42; P<0.001). Univariate regression analysis revealed that nitroglycerine-induced vasodilation correlated with age (r=−0.34; P<0.001), systolic blood pressure (r=−0.32; P<0.001), diastolic blood pressure (r=−0.24; P<0.001), heart rate (r=−0.21; P<0.001), glucose (r=−0.23; P<0.001), and smoking pack-year (r=−0.12; P=0.01), as well as Framingham risk score (r=−0.30; P<0.001). Nitroglycerine-induced vasodilation was significantly smaller in patients with cardiovascular disease than in both subjects with and without cardiovascular risk factors (10.5±5.6% versus 13.7±5.4% and 15.3±4.3%; P<0.001, respectively), whereas there was no significant difference in nitroglycerine-induced vasodilation between subjects with and without cardiovascular risk factors. Multivariate analysis revealed that male sex, body mass index, hypertension, diabetes mellitus, baseline brachial artery diameter, and FMD were independent predictors of nitroglycerine-induced vasodilation. Conclusions—These findings suggest that nitroglycerine-induced vasodilation may be a marker of the grade of atherosclerosis. FMD should be interpreted as an index of vascular function reflecting both endothelium-dependent vasodilation and endothelium-independent vasodilation in subjects with impaired nitroglycerine-induced vasodilation.Objective— Nitroglycerine-induced vasodilation has been used as a control test for flow-mediated vasodilation (FMD) to differentiate endothelium-dependent from endothelium-independent response when evaluating endothelial function in humans. Recently, nitroglycerine-induced vasodilation has also been reported to be impaired in patients with atherosclerosis. The purpose of this study was to determine the relationships between nitroglycerine-induced vasodilation and cardiovascular risk factors. Approach and Results— We measured nitroglycerine-induced vasodilation and FMD in 436 subjects who underwent health examinations (mean age, 53±19 years; age range, 19–86 years), including patients with cardiovascular diseases. There was a significant relationship between nitroglycerine-induced vasodilation and FMD ( r =0.42; P <0.001). Univariate regression analysis revealed that nitroglycerine-induced vasodilation correlated with age ( r =−0.34; P <0.001), systolic blood pressure ( r =−0.32; P <0.001), diastolic blood pressure ( r =−0.24; P <0.001), heart rate ( r =−0.21; P <0.001), glucose ( r =−0.23; P <0.001), and smoking pack-year ( r =−0.12; P =0.01), as well as Framingham risk score ( r =−0.30; P <0.001). Nitroglycerine-induced vasodilation was significantly smaller in patients with cardiovascular disease than in both subjects with and without cardiovascular risk factors (10.5±5.6% versus 13.7±5.4% and 15.3±4.3%; P <0.001, respectively), whereas there was no significant difference in nitroglycerine-induced vasodilation between subjects with and without cardiovascular risk factors. Multivariate analysis revealed that male sex, body mass index, hypertension, diabetes mellitus, baseline brachial artery diameter, and FMD were independent predictors of nitroglycerine-induced vasodilation. Conclusions— These findings suggest that nitroglycerine-induced vasodilation may be a marker of the grade of atherosclerosis. FMD should be interpreted as an index of vascular function reflecting both endothelium-dependent vasodilation and endothelium-independent vasodilation in subjects with impaired nitroglycerine-induced vasodilation. # Significance {#article-title-30}


Arteriosclerosis, Thrombosis, and Vascular Biology | 2011

Rho-Associated Kinase Activity, Endothelial Function, and Cardiovascular Risk Factors

Junko Soga; Kensuke Noma; Takaki Hata; Takayuki Hidaka; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Shinsuke Mikami; Tatsuya Maruhashi; Yasuki Kihara; Kazuaki Chayama; Hitoshi Kato; James K. Liao; Yukihito Higashi

Objective—Cardiovascular diseases are associated with chronic activation of Rho-associated kinases (ROCKs) and endothelial dysfunction. Both increased ROCK activity and endothelial dysfunction are thought to be closely associated with conventional cardiovascular risk factors. The purpose of this study was to determine the relationships between ROCK activity, endothelial function, and cardiovascular risk factors. Methods and Results—We evaluated ROCK activity in peripheral leukocytes by Western blot analysis and flow-mediated vasodilation by ultrasonography in 242 men who had no cardiovascular or cerebrovascular diseases (mean age, 40±10 years; range, 20 to 73 years). ROCK activity was defined as the ratio of phospho myosin-binding subunit on myosin light chain phosphatase to total myosin-binding subunit. Univariate regression analysis revealed that leukocyte ROCK activity significantly correlated with body mass index (r=0.29, P=0.003); systolic blood pressure (r=0.25, P=0.01); low-density lipoprotein cholesterol level (r=0.21, P=0.04); and Framingham risk factor score, a cumulative cardiovascular risk index for heart attack (r=0.31, P<0.001), and that flow-mediated vasodilation significantly correlated with age (r=−0.23, P=0.02), body mass index (r=0.19, P=0.05), systolic blood pressure (r=−0.22, P=0.03), total cholesterol level (r=−0.21, P=0.04), low-density lipoprotein cholesterol level (r=−0.22, P=0.04), glucose level (r=−0.20, P=0.04), and Framingham risk factor score (r=−0.37, P<0.001). There was a significant correlation between leukocyte ROCK activity and flow-mediated vasodilation (r=−0.41, P<0.001). Multivariate analysis revealed that flow-mediated vasodilation was an independent predictor of leukocyte ROCK activity. Conclusion—These findings suggest that cumulative cardiovascular risk may enhance ROCK activity and endothelial dysfunction, leading to progression of cardiovascular diseases and outcomes.


Clinical Pharmacology & Therapeutics | 2012

Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho‐Associated Kinase Activity in Patients With Hypertension

Noritaka Fujimura; Kensuke Noma; Takaki Hata; Jyunko Soga; Toru Hidaka; Naomi Idei; Yuichi Fujii; Shinsuke Mikami; Tatsuya Maruhashi; Yumiko Iwamoto; Yasuki Kihara; Kazuaki Chayama; Hitoshi Kato; James K. Liao; Yukihito Higashi

Hypertension is associated with endothelial dysfunction and activated Rho‐associated kinases (ROCKs). The purpose of this study was to evaluate the effects of the selective mineralocorticoid receptor blocker, eplerenone, on endothelial function and ROCK activity in patients with hypertension. The study was carried out over 48 weeks in 60 untreated patients with hypertension who were randomly assigned to eplerenone, nifedipine, and losartan groups. We evaluated the effects of each treatment on flow‐mediated vasodilation (FMD) and ROCK activity in peripheral leukocytes. Eplerenone increased FMD and decreased leukocyte ROCK activity. Nifedipine decreased ROCK activity but did not alter FMD. Losartan increased FMD but did not alter ROCK activity. Hypotensive effects were similar in the three groups, as was nitroglycerin‐induced vasodilation during the follow‐up period. There were no significant differences between the groups with respect to other parameters. The study results show that eplerenone improves endothelial function and inhibits ROCK activity in patients with essential hypertension.


Heart | 2013

Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study

Tatsuya Maruhashi; Junko Soga; Noritaka Fujimura; Naomi Idei; Shinsuke Mikami; Yumiko Iwamoto; Masato Kajikawa; Takeshi Matsumoto; Takayuki Hidaka; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; Ayumu Nakashima; Chikara Goto; Hirofumi Tomiyama; Bonpei Takase; Akira Yamashina; Yukihito Higashi

Objective To determine the relationships between flow-mediated vasodilation (FMD) and cardiovascular risk factors, and to evaluate confounding factors for measurement of FMD in a large general population in Japan. Methods This was a cross-sectional study. A total of 5314 Japanese adults recruited from people who underwent health screening from 1 April 2010 to 31 August 2012 at 3 general hospitals in Japan. Patients’ risk factors (age, Body Mass Index, blood pressure, cholesterol parameters, glucose level and HbA1c level) and prevalence of cardiovascular disease (coronary heart disease and cerebrovascular disease) were investigated. Results Univariate regression analysis revealed that FMD correlated with age (r=−0.27, p<0.001), Body Mass Index (r=−0.14, p<0.001), systolic blood pressure (r=−0.18, p<0.001), diastolic blood pressure (r=−0.13, p<0.001), total cholesterol (r=−0.07, p<0.001), triglycerides (r=−0.10, p<0.001), high-density lipoprotein cholesterol (r=0.06, p<0.001), low-density lipoprotein cholesterol (r=−0.04, p=0.01), glucose level (r=−0.14, p<0.001), HbA1c (r=−0.14, p<0.001), and baseline brachial artery diameter (r=−0.43, p<0.001) as well as Framingham Risk score (r=−0.29, p<0.001). Multivariate analysis revealed that age (t value=−9.17, p<0.001), sex (t value=9.29, p<0.001), Body Mass Index (t value=4.27, p<0.001), systolic blood pressure (t value=−2.86, p=0.004), diabetes mellitus (t value=−4.19, p<0.001), smoking (t value=−2.56, p=0.01), and baseline brachial artery diameter (t value=−29.4, p<0.001) were independent predictors of FMD. Conclusions FMD may be a marker of the grade of atherosclerosis and may be used as a surrogate marker of cardiovascular outcomes. Age, sex, Body Mass Index, systolic blood pressure, diabetes mellitus, smoking and, particularly, baseline brachial artery diameter are potential confounding factors in the measurement of FMD.


Diabetes Care | 2015

Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is A Predictor of Endothelial Function

Masato Kajikawa; Ayumu Nakashima; Noritaka Fujimura; Tatsuya Maruhashi; Yumiko Iwamoto; Akimichi Iwamoto; Takeshi Matsumoto; Nozomu Oda; Takayuki Hidaka; Yasuki Kihara; Kazuaki Chayama; Chikara Goto; Yoshiki Aibara; Kensuke Noma; Masayoshi Takeuchi; Takanori Matsui; Sho-ichi Yamagishi; Yukihito Higashi

OBJECTIVE Advanced glycation end products (AGEs) and their specific receptor, the receptor for AGEs (RAGE), play an important role in atherosclerosis. Recently, a soluble form of RAGE (sRAGE) has been identified in human serum. However, the role of sRAGE in cardiovascular disease is still controversial. There is no information on the association between simultaneous measurements of AGEs and sRAGE and vascular function. In this study, we evaluated the associations between serum levels of AGEs and sRAGE, ratio of AGEs to sRAGE, and vascular function. RESEARCH DESIGN AND METHODS We measured serum levels of AGEs and sRAGE and assessed vascular function by measurement of flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation in 110 subjects who underwent health examinations. Multivariate regression analyses were performed to identify factors associated with vascular function. RESULTS Univariate regression analysis revealed that FMD correlated with age, BMI, systolic blood pressure, diastolic blood pressure, heart rate, triglycerides, HDL cholesterol, glucose, smoking pack-years, nitroglycerine-induced vasodilation, serum levels of AGEs and sRAGE, and ratio of AGEs to sRAGE. Multivariate analysis revealed that the ratio of AGEs to sRAGE remained an independent predictor of FMD, while serum level of AGEs alone or sRAGE alone was not associated with FMD. CONCLUSIONS These findings suggest that sRAGE may have a counterregulatory mechanism that is activated to counteract the vasotoxic effect of the AGE–RAGE axis. The ratio of AGEs to sRAGE may be a new chemical biomarker of endothelial function.


Circulation-cardiovascular Interventions | 2011

Autologous Bone-Marrow Mononuclear Cell Implantation Reduces Long-Term Major Amputation Risk in Patients With Critical Limb Ischemia

Naomi Idei; Junko Soga; Takaki Hata; Yuichi Fujii; Noritaka Fujimura; Shinsuke Mikami; Tatsuya Maruhashi; Kenji Nishioka; Takayuki Hidaka; Yasuki Kihara; Moniruddin Chowdhury; Kensuke Noma; Akira Taguchi; Kazuaki Chayama; Taijiro Sueda; Yukihito Higashi

Background— Bone-marrow mononuclear cell (BM-MNC) implantation improves ischemic symptoms in patients with critical limb ischemia (CLI). The purpose of this study was to evaluate long-term clinical outcomes after autologous BM-MNC implantation in patients with CLI. Methods and Results— We assessed long-term clinical outcomes after BM-MNC implantation in 51 patients with CLI, including 25 patients with peripheral arterial disease (PAD) and 26 patients with Buerger disease. Forty-six CLI patients who had no BM-MNC implantation served as control subjects. Median follow-up period was 4.8 years. The 4-year amputation-free rates after BM-MNC implantation were 48% in PAD patients and 95% in Buerger disease, and they were 0% in control PAD patients and 6% in control Buerger disease. The 4-year overall survival rates after BM-MNC implantation were 76% in PAD patients and 100% in Buerger disease, and they were 67% in control PAD patients and 100% in control Buerger disease. Multivariable Cox proportional hazards analysis revealed that BM-MNC implantation correlated with prevention of major amputation and that hemodialysis and diabetes mellitus correlated with major amputation. In Buerger disease, ankle brachial pressure index and transcutaneous oxygen pressure were significantly increased after 1 month and remained high during 3-year follow-up. However, in patients with PAD, ankle brachial pressure index and transcutaneous oxygen pressure significantly increased after 1 month and gradually decreased during 3-year follow-up and returned to baseline levels. Conclusions— These findings suggest that BM-MNC implantation is safe and effective in patients with CLI, especially in patients with Buerger disease. Clinical Trial Registration— URL: . Unique identifier: 001769.Background—Bone-marrow mononuclear cell (BM-MNC) implantation improves ischemic symptoms in patients with critical limb ischemia (CLI). The purpose of this study was to evaluate long-term clinical outcomes after autologous BM-MNC implantation in patients with CLI. Methods and Results—We assessed long-term clinical outcomes after BM-MNC implantation in 51 patients with CLI, including 25 patients with peripheral arterial disease (PAD) and 26 patients with Buerger disease. Forty-six CLI patients who had no BM-MNC implantation served as control subjects. Median follow-up period was 4.8 years. The 4-year amputation-free rates after BM-MNC implantation were 48% in PAD patients and 95% in Buerger disease, and they were 0% in control PAD patients and 6% in control Buerger disease. The 4-year overall survival rates after BM-MNC implantation were 76% in PAD patients and 100% in Buerger disease, and they were 67% in control PAD patients and 100% in control Buerger disease. Multivariable Cox proportional hazards analysis revealed that BM-MNC implantation correlated with prevention of major amputation and that hemodialysis and diabetes mellitus correlated with major amputation. In Buerger disease, ankle brachial pressure index and transcutaneous oxygen pressure were significantly increased after 1 month and remained high during 3-year follow-up. However, in patients with PAD, ankle brachial pressure index and transcutaneous oxygen pressure significantly increased after 1 month and gradually decreased during 3-year follow-up and returned to baseline levels. Conclusions—These findings suggest that BM-MNC implantation is safe and effective in patients with CLI, especially in patients with Buerger disease. Clinical Trial Registration—URL: http://home.hiroshima-u.ac.jp/angio/. Unique identifier: 001769.

Collaboration


Dive into the Tatsuya Maruhashi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge